{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-086368","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.941171+00:00","generated_at":"2026-06-12T16:37:00.838756+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rigel Q2 net loss narrows to $6.6M; TAVALISSE sales up 15% YoY to $21.3M","bullets":["Q2 net loss $6.6M ($0.04/sh) vs $13.5M loss in Q2 2022; total revenue $26.9M.","TAVALISSE net product sales $21.3M (+15% YoY); REZLIDHIA sales $2.6M with 77% sequential bottle growth.","Cash, equivalents & investments $64.4M at June 30, up from $58.2M at Dec 31, 2022.","R289 Phase 1b in LR-MDS completed cohort 2 enrollment; R552 Phase 2a in RA initiated by Eli Lilly."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-086368","json":"https://secwatch.observer/filing/0001104659-23-086368.json","markdown":"https://secwatch.observer/filing/0001104659-23-086368.md","text":"https://secwatch.observer/filing/0001104659-23-086368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923086368/0001104659-23-086368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923086368/tm2322488d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T16:37:00.838756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1f2d3b87ac7a9a8750ad404225ad6ccd93b1cd7","claim":"RIGEL PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $26.9 million, net income net loss of $6.6 million, EPS $0.04 per basic and diluted share.","evidence_excerpt":"For the second quarter of 2023, Rigel reported a net loss of $6.6 million, or $0.04 per basic and diluted share, compared to a net loss of $13.5 million, or $0.08 per basic and diluted share, for the same period of 2022. For the second quarter of 2023, total revenues were $26.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923086368/0001104659-23-086368-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$26.9 million"},{"label":"Net income","value":"net loss of $6.6 million"},{"label":"EPS","value":"$0.04 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c790f0375c3285c5ae20fc68b82eb7ff3f750596","claim":"RIGEL PHARMACEUTICALS INC reported the six months ended June 30, 2023 results: revenue $52.9 million, net income net loss of $20.1 million, EPS $0.12 per basic and diluted share.","evidence_excerpt":"For the six months ended June 30, 2023, Rigel reported a net loss of $20.1 million, or $0.12 per basic and diluted share, compared to a net loss of $40.9 million, or $0.24 per basic and diluted share, for the same period of 2022. For the six months ended June 30, 2023, total revenues were $52.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923086368/0001104659-23-086368-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Revenue","value":"$52.9 million"},{"label":"Net income","value":"net loss of $20.1 million"},{"label":"EPS","value":"$0.12 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}